Scribe Therapeutics announced plans to start the first human test of a CRISPR‑based cholesterol‑lowering therapy this summer, marking a near‑term clinical debut for a company built on engineered CRISPR enzymes. The move follows years of discovery of novel CRISPR nucleases and positions Scribe among gene‑editing firms advancing in‑patient programs. Separately, researchers reported therapeutic potential for CRISPR–Cas3 in preclinical models and described Cas3’s mechanistic differences from Cas9, highlighting opportunities for permanent gene disruption in diseases such as transthyretin amyloidosis. Both developments underscore multiple CRISPR modalities moving toward translational milestones.